FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2034064057> ?p ?o ?g. }

• W2034064057 endingPage "249" @default.
• W2034064057 startingPage "249" @default.
• W2034064057 abstract "Primary Sjögren syndrome is a systemic autoimmune disease characterized by mouth and eye dryness, pain, and fatigue. Hydroxychloroquine is the most frequently prescribed immunosuppressant for the syndrome. However, evidence regarding its efficacy is limited.To evaluate the efficacy of hydroxychloroquine for the main symptoms of primary Sjögren syndrome: dryness, pain, and fatigue.From April 2008 to May 2011, 120 patients with primary Sjögren syndrome according to American-European Consensus Group Criteria from 15 university hospitals in France were randomized in a double-blind, parallel-group, placebo-controlled trial. Participants were assessed at baseline, week 12, week 24 (primary outcome), and week 48. The last follow-up date for the last patient was May 15, 2012.Patients were randomized (1:1) to receive hydroxychloroquine (400 mg/d) or placebo until week 24. All patients were prescribed hydroxychloroquine between weeks 24 and 48.The primary end point was the proportion of patients with a 30% or greater reduction between weeks 0 and 24 in scores on 2 of 3 numeric analog scales (from 0 [best] to 10 [worst]) evaluating dryness, pain, and fatigue.At 24 weeks, the proportion of patients meeting the primary end point was 17.9% (10/56) in the hydroxychloroquine group and 17.2% (11/64) in the placebo group (odds ratio, 1.01; 95% CI, 0.37-2.78; P = .98). Between weeks 0 and 24, the mean (SD) numeric analog scale score for dryness changed from 6.38 (2.14) to 5.85 (2.57) in the placebo group and 6.53 (1.97) to 6.22 (1.87) in the hydroxychloroquine group. The mean (SD) numeric analog scale score for pain changed from 4.92 (2.94) to 5.08 (2.48) in the placebo group and 5.09 (3.06) to 4.59 (2.90) in the hydroxychloroquine group. The mean (SD) numeric analog scale for fatigue changed from 6.26 (2.27) to 5.72 (2.38) in the placebo group and 6.00 (2.52) to 5.94 (2.40) in the hydroxychloroquine group. All but 1 patient in the hydroxychloroquine group had detectable blood levels of the drug. Hydroxychloroquine had no efficacy in patients with anti-SSA autoantibodies, high IgG levels, or systemic involvement. During the first 24 weeks, there were 2 serious adverse events in the hydroxychloroquine group and 3 in the placebo group; in the last 24 weeks, there were 3 serious adverse events in the hydroxychloroquine group and 4 in the placebo group.Among patients with primary Sjögren syndrome, the use of hydroxychloroquine compared with placebo did not improve symptoms during 24 weeks of treatment. Further studies are needed to evaluate longer-term outcomes.clinicaltrials.gov Identifier: NCT00632866." @default.
• W2034064057 created "2016-06-24" @default.
• W2034064057 creator A5002774188 @default.
• W2034064057 creator A5007820039 @default.
• W2034064057 creator A5022109878 @default.
• W2034064057 creator A5025160491 @default.
• W2034064057 creator A5032316254 @default.
• W2034064057 creator A5032875267 @default.
• W2034064057 creator A5035772780 @default.
• W2034064057 creator A5037025760 @default.
• W2034064057 creator A5038404944 @default.
• W2034064057 creator A5041964302 @default.
• W2034064057 creator A5050180409 @default.
• W2034064057 creator A5050659517 @default.
• W2034064057 creator A5051196993 @default.
• W2034064057 creator A5052281241 @default.
• W2034064057 creator A5055588232 @default.
• W2034064057 creator A5058246614 @default.
• W2034064057 creator A5060793051 @default.
• W2034064057 creator A5067722218 @default.
• W2034064057 creator A5068916735 @default.
• W2034064057 creator A5069264280 @default.
• W2034064057 creator A5076759724 @default.
• W2034064057 creator A5080881858 @default.
• W2034064057 creator A5081030581 @default.
• W2034064057 date "2014-07-16" @default.
• W2034064057 modified "2023-10-17" @default.
• W2034064057 title "Effects of Hydroxychloroquine on Symptomatic Improvement in Primary Sjögren Syndrome" @default.
• W2034064057 cites W1903233379 @default.
• W2034064057 cites W1967834717 @default.
• W2034064057 cites W1971387596 @default.
• W2034064057 cites W2005937589 @default.
• W2034064057 cites W2010111291 @default.
• W2034064057 cites W2022755336 @default.
• W2034064057 cites W2023483536 @default.
• W2034064057 cites W2024235155 @default.
• W2034064057 cites W2051649686 @default.
• W2034064057 cites W2054979867 @default.
• W2034064057 cites W2059189040 @default.
• W2034064057 cites W2064439068 @default.
• W2034064057 cites W2078958726 @default.
• W2034064057 cites W2084507136 @default.
• W2034064057 cites W2085412199 @default.
• W2034064057 cites W2097783436 @default.
• W2034064057 cites W2105452082 @default.
• W2034064057 cites W2114850377 @default.
• W2034064057 cites W2117738981 @default.
• W2034064057 cites W2118400571 @default.
• W2034064057 cites W2120282676 @default.
• W2034064057 cites W2159708138 @default.
• W2034064057 cites W2162677632 @default.
• W2034064057 cites W2167385753 @default.
• W2034064057 cites W2168030824 @default.
• W2034064057 cites W2169152490 @default.
• W2034064057 cites W2171751598 @default.
• W2034064057 doi "https://doi.org/10.1001/jama.2014.7682" @default.
• W2034064057 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/25027140" @default.
• W2034064057 hasPublicationYear "2014" @default.
• W2034064057 type Work @default.
• W2034064057 sameAs 2034064057 @default.
• W2034064057 citedByCount "228" @default.
• W2034064057 countsByYear W20340640572013 @default.
• W2034064057 countsByYear W20340640572014 @default.
• W2034064057 countsByYear W20340640572015 @default.
• W2034064057 countsByYear W20340640572016 @default.
• W2034064057 countsByYear W20340640572017 @default.
• W2034064057 countsByYear W20340640572018 @default.
• W2034064057 countsByYear W20340640572019 @default.
• W2034064057 countsByYear W20340640572020 @default.
• W2034064057 countsByYear W20340640572021 @default.
• W2034064057 countsByYear W20340640572022 @default.
• W2034064057 countsByYear W20340640572023 @default.
• W2034064057 crossrefType "journal-article" @default.
• W2034064057 hasAuthorship W2034064057A5002774188 @default.
• W2034064057 hasAuthorship W2034064057A5007820039 @default.
• W2034064057 hasAuthorship W2034064057A5022109878 @default.
• W2034064057 hasAuthorship W2034064057A5025160491 @default.
• W2034064057 hasAuthorship W2034064057A5032316254 @default.
• W2034064057 hasAuthorship W2034064057A5032875267 @default.
• W2034064057 hasAuthorship W2034064057A5035772780 @default.
• W2034064057 hasAuthorship W2034064057A5037025760 @default.
• W2034064057 hasAuthorship W2034064057A5038404944 @default.
• W2034064057 hasAuthorship W2034064057A5041964302 @default.
• W2034064057 hasAuthorship W2034064057A5050180409 @default.
• W2034064057 hasAuthorship W2034064057A5050659517 @default.
• W2034064057 hasAuthorship W2034064057A5051196993 @default.
• W2034064057 hasAuthorship W2034064057A5052281241 @default.
• W2034064057 hasAuthorship W2034064057A5055588232 @default.
• W2034064057 hasAuthorship W2034064057A5058246614 @default.
• W2034064057 hasAuthorship W2034064057A5060793051 @default.
• W2034064057 hasAuthorship W2034064057A5067722218 @default.
• W2034064057 hasAuthorship W2034064057A5068916735 @default.
• W2034064057 hasAuthorship W2034064057A5069264280 @default.
• W2034064057 hasAuthorship W2034064057A5076759724 @default.
• W2034064057 hasAuthorship W2034064057A5080881858 @default.
• W2034064057 hasAuthorship W2034064057A5081030581 @default.
• W2034064057 hasConcept C126322002 @default.
• W2034064057 hasConcept C14184104 @default.

• next